Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 clinical study evaluating the safety and efficacy of GT719 universal cell injection for immune-mediated kidney diseases is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Glomerulonephritis
• Anca-associated Vasculitis
• Iga Nephropathy
• Membranous Nephropathy
• Podocytopathy
• Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits

Drugs mentioned

• GT719 Universal Cell Injection

Snippet

Sponsor: Grit Biotechnology | Conditions: IgA Nephropathy (IgAN), Membranous Nephropathy | EARLY_Phase 1 | Status: NOT_YET_RECRUITING